Scientia Ventures
VC Fund
New York, United States
Scientia Ventures is a VC fund in New York focused on Medical and Health Care. Scientia Ventures invests in early to mid-stage technology companies that target computational biology and chemistry, the digitization of medicine, and digital therapies as well as traditional drug development companies at the cutting edge of the life sciences.
- Total investments:
- 5
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Scientia Ventures invests in
Stages Scientia Ventures invests in
Countries Scientia Ventures invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
4 more contacts available
Investment Focus
Industry
- Medical 2 (40%)
- Health Care 2 (40%)
- mHealth 1 (20%)
- Software 1 (20%)
- Wellness 1 (20%)
Stage
- Seed 3 (60%)
- Series B 1 (20%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Harry Glorikian
General Partner
|
General Partner | Total investments: 3 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
|
|
IntelinAir is an aerial imagery analytics company focused on agriculture that delivers actionable intelligence to help farmers make data-driven decisions to improve operational efficiency, yields, and ultimately their profitability. | $20M / Series B / Sep 23, 2021 | |
|
|
Humanity is a healthcare company that aims to extend the healthspan of humanity. It develops a software application designed to provide information on how to stop the aging process. The company's service allows people to try different interventions and solutions to help move those biomarkers in a positive direction and thus reduce, and in somecases, stop the loss of function and thus the aging damage.Founded in 2019 by Peter Ward and Michael Geer, Humanity is headquartered in Boston, Massachusetts. | $2.5M / Seed / Aug 04, 2021 | |
|
|
Humanity is a healthcare company that aims to extend the healthspan of humanity. It develops a software application designed to provide information on how to stop the aging process. The company's service allows people to try different interventions and solutions to help move those biomarkers in a positive direction and thus reduce, and in somecases, stop the loss of function and thus the aging damage.Founded in 2019 by Peter Ward and Michael Geer, Humanity is headquartered in Boston, Massachusetts. | $2.5M / Seed / Aug 04, 2021 | |
|
|
1910 Genetics is a biotechnology company integrating AI, computation, and biological automation to improve drug development. The company establishes an understanding of the molecular basis of disease to the granularity at which the world understands sickle cell anemia. This understanding drives their integration of artificial intelligence (AI),computation, and biological automation to accelerate the design of small molecule and protein therapeutics. | $4.1M / Seed / Mar 31, 2020 | |
|
|
Cristcot focuses on drug delivery systems that combine products and specialty drug formulations. Its current products and pipeline of future products are focused in the areas of gastroenterology, neurology, and pain management. | Seed / Jan 01, 2010 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Scientia Ventures invest in?
Scientia Ventures invests primarily in Medical, Health Care and mHealth startups, most often at Seed and Series B stage. Most of the 5 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Scientia Ventures?
Public channels for Scientia Ventures include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Scientia Ventures?
The team at Scientia Ventures includes Harry Glorikian (General Partner). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!